A Phase 1 First-in-human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 427 in Subjects with Relapsed/Refractory Acute Myeloid Leukemia
Clinical Trial Grant
Awarded By
Amgen, Inc.
Start Date
August 7, 2020
End Date
February 28, 2024
Awarded By
Amgen, Inc.
Start Date
August 7, 2020
End Date
February 28, 2024